Giandomenico Roviello1,2, Laura Zanotti2, Pierpaolo Correale3, Angela Gobbi2, Simon Wigfield4, Alessandra Guglielmi5, Chiara Pacifico3, Daniele Generali2,6. 1. Department of Molecular & Translational Medicine, University of Brescia, 25123 Brescia, Italy. 2. Unit of Molecular Therapy & Pharmacogenomics, ASST Cremona, Viale Concordia 1, 26100 Cremona, Italy. 3. Unit of Radiotherapy, Department of Medical, Surgical Sciences & Neurosciences, Siena University, Viale Bracci 11, 53100 Siena, Italy. 4. Department of Oncology, Molecular Oncology Laboratories, The Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital Headley Way, Headington, Oxford, OX3 9DS, UK. 5. Unit of medical oncology, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy. 6. Department of Medical, Surgery & Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy.
Abstract
AIM: IL-2 is one of the first immunomodulating cytokines to be tested in the treatment of cancer patients. The effects of this agent in the treatment of solid tumors other than renal cancer and melanoma are poorly understood. MATERIALS & METHODS: We have carried out a meta-analysis of randomized studies. We fixed the response rate as the primary outcome. RESULTS: The pooled risk ratio for an objective response with IL-2 plus chemotherapy versus chemotherapy alone was 1.43 (95% CI: 1.12-1.81; p = 0.004), in favor of colorectal cancer. CONCLUSION: Further investigation in the treatment of patients with colorectal cancer or other solid malignancies with IL-2 is required, alone or in combination with chemotherapy.
AIM: IL-2 is one of the first immunomodulating cytokines to be tested in the treatment of cancerpatients. The effects of this agent in the treatment of solid tumors other than renal cancer and melanoma are poorly understood. MATERIALS & METHODS: We have carried out a meta-analysis of randomized studies. We fixed the response rate as the primary outcome. RESULTS: The pooled risk ratio for an objective response with IL-2 plus chemotherapy versus chemotherapy alone was 1.43 (95% CI: 1.12-1.81; p = 0.004), in favor of colorectal cancer. CONCLUSION: Further investigation in the treatment of patients with colorectal cancer or other solid malignancies with IL-2 is required, alone or in combination with chemotherapy.
Authors: Karl-Frederick Karstens; Jan Kempski; Anastasios D Giannou; Erik Freiwald; Matthias Reeh; Michael Tachezy; Jakob R Izbicki; Ansgar W Lohse; Nicola Gagliani; Samuel Huber; Penelope Pelczar Journal: PLoS One Date: 2020-04-16 Impact factor: 3.240